ESMO 2020

REVIEW UroToday

Viewing 1-20 of 154 articles

ESMO Virtual Congress 2020: Complex Biomarkers in Drug Development

ESMO Virtual Congress 2020: Clinical Factors That Are Prognostic for Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

ESMO Virtual Congress 2020: Darolutamide, Enzalutamide and Apalutamide the Risk of Adverse Events in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Number Needed to Harm

ESMO Virtual Congress 2020: Quality of Life and Survival in Elderly Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel

ESMO Virtual Congress 2020: Real-World Patterns of Genomic Testing in Patients with Metastatic Castration-Resistant Prostate Cancer

ESMO Virtual Congress 2020: Pembrolizumab plus Docetaxel and Prednisone in Patients with Abiraterone Acetate– or Enzalutamide–Pretreated Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort B Update

ESMO Virtual Congress 2020: NRG Oncology’s GU007 (NADIR): Niraparib with Standard Combination with ADT and Radiotherapy in High-Risk Prostate Cancer

ESMO Virtual Congress 2020: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP 1801)

ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Results from Cohort 10 of the COSMIC-021 Study

ESMO Virtual Congress 2020: Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma: Extended Follow-Up from CheckMate 032

ESMO Virtual Congress 2020: Molecular Profiling of Post-pembrolizumab Muscle-Invasive Bladder Cancer Reveals Unique Features That May Inspire New Sequential Therapies in Pathological Non-responders

ESMO Virtual Congress 2020: Real-World Evidence of the Impact of Prior Autoimmune Disease on Immune Checkpoint Inhibitor Outcomes in Patients with Metastatic Urothelial Cancer

ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 3: Sacituzumab Govitecan and Pembrolizumab in Patients with Progression or Recurrence of Metastatic Urothelial Cancer after Platinum -Based Therapy

ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus Pembrolizumab and/or Chemotherapy, vs Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer

ESMO Virtual Congress 2020: Tumour-Only Sequencing Led to Inflated Tumour Mutational Burden Estimation Especially in Under-Represented Ethnic Groups

ESMO Virtual Congress 2020: Treatment in CARD Eligible Metastatic Castration Resistant Prostate Cancer Patients According to the Status of Germline HRR Mutations: Cabazitaxel vs Enzalutamide/Abiraterone

ESMO Virtual Congress 2020: Pan-Cancer Analysis of Homologous Recombination Associated Alterations and Genome-Wide Loss of Heterozygosity

ESMO Virtual Congress 2020: Invited Discussant: (617MO) Repurposing Metformin as Anticancer Drug (MANSMED) and (618MO) Local Therapy to the Primary Tumour for Newly Diagnosed, Oligo-Metastatic Prostate Cancer

ESMO Virtual Congress 2020: PROREPAIR-A Study Results: Clinical Impact of Somatic Alterations in Prostate Cancer Patients with and without Previously Known Germline BRCA1/2 Mutations

ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma

1
2
3
4
5
6
7
8